CYG
CYCN icon

Clean Yield Group’s Cyclerion Therapeutics CYCN Stock Holding History

Clean Yield Group’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-6
Closed -$50 – 413
2023
Q1 		$50 Hold
6
– – ﹤0.01% 419
2022
Q4 		$75 Hold
6
– – ﹤0.01% 450
2022
Q3 		$0 Hold
6
– – ﹤0.01% 462
2022
Q2 		$0 Hold
6
– – ﹤0.01% 428
2022
Q1 		$0 Hold
6
– – ﹤0.01% 477
2021
Q4 		$0 Hold
6
– – ﹤0.01% 455
2021
Q3 		$0 Hold
6
– – ﹤0.01% 474
2021
Q2 		$0 Buy
+6
New +$376 ﹤0.01% 457

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Clean Yield Group's CYCN Position: Q2 2023 in Review

Clean Yield Group sold out of Cyclerion Therapeutics (CYCN) in Q2 2023, closing a stake of 6 shares — an estimated $50 sold.

Clean Yield Group first reported a position in CYCN in Q2 2021 and held it in 8 quarters. The position peaked at $75 in Q4 2022. 18 funds tracked by Wall St. Rank hold CYCN as of Q2 2023.

  • Clean Yield Group reported no remaining Cyclerion Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Clean Yield Group sold 6 Cyclerion Therapeutics shares in Q2 2023, an estimated $50.
  • Clean Yield Group first reported a position in Cyclerion Therapeutics in Q2 2021 and held it in 8 quarters.
  • Clean Yield Group's Cyclerion Therapeutics position peaked at $75 in Q4 2022.
  • 18 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2023.

Based on Clean Yield Group's 13F filing for Q2 2023, filed 26 Jul 2023.